Eosinophilic bioactivities in severe asthma
Publisher DOI
PubMed ID
27386041
Abstract
Asthma is clearly related to airway or blood eosinophilia, and asthmatics with significant eosinophilia are at higher risk for more severe disease. Eosinophils actively contribute to innate and adaptive immune responses and inflammatory cascades through the production and release of diverse chemokines, cytokines, lipid mediators and other growth factors. Eosinophils may persist in the blood and airways despite guidelines-based treatment. This review details eosinophil effector mechanisms, surface markers, and clinical outcomes associated with eosinophilia and asthma severity. There is interest in the potential of eosinophils or their products to predict treatment response with biotherapeutics and their usefulness as biomarkers. This is important as monoclonal antibodies are targeting cytokines and eosinophils in different lung environments for treating severe asthma. Identifying disease state-specific eosinophil biomarkers would help to refine these strategies and choose likely responders to biotherapeutics.
Date Issued
2016
Publication Type
Article
Subject(s)
Subjects
Bioactivities
•
Biotherapeutics
•
Eosinophilia
•
Eosinophils
•
Severe asthma
Language(s)
en
Author(s)
Carr, Tara F | |
Berdnikovs, Sergejs | |
Bochner, Bruce S | |
Rosenwasser, Lanny J |
Additional Credits
Journal
World Allergy Organization journal
Publisher
BioMed Central
ISSN
1939-4551
Access(Rights)
open.access